Switch theme
Sign up to access all valuation multiples
Voronoi Inc is a biotech company that develops novel kinase inhibitors and targets protein degraders.
2015
n/a
LTM Revenue $6.7M
LTM EBITDA -$17.7M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Voronoi has a last 12-month revenue of $6.7M and a last 12-month EBITDA of -$17.7M.
In the most recent fiscal year, Voronoi achieved revenue of n/a and an EBITDA of -$20.5M.
Voronoi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Voronoi valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | $6.7M | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$21.5M | -$20.5M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$13.6M | -$25.1M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | $9.7M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Voronoi's stock price is KRW 115600 (or $79).
Voronoi has current market cap of KRW 2.08T (or $1.4B), and EV of KRW 2.02T (or $1.4B).
See Voronoi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.4B | XXX | XXX | XXX | XXX | $-1.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Voronoi has market cap of $1.4B and EV of $1.4B.
Voronoi's trades at 206.7x LTM EV/Revenue multiple, and -77.9x LTM EBITDA.
Analysts estimate Voronoi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Voronoi and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -67.2x | XXX | XXX | XXX |
| P/E | -63.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -66.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVoronoi's NTM/LTM revenue growth is 224%
Voronoi's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Voronoi's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Voronoi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Voronoi and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Voronoi acquired XXX companies to date.
Last acquisition by Voronoi was XXXXXXXX, XXXXX XXXXX XXXXXX . Voronoi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Voronoi founded? | Voronoi was founded in 2015. |
| Where is Voronoi headquartered? | Voronoi is headquartered in South Korea. |
| Who is the CEO of Voronoi? | Voronoi's CEO is Mr. Hyun-Tae Kim. |
| Is Voronoi publicy listed? | Yes, Voronoi is a public company listed on KRX. |
| What is the stock symbol of Voronoi? | Voronoi trades under 310210 ticker. |
| When did Voronoi go public? | Voronoi went public in 2022. |
| Who are competitors of Voronoi? | Similar companies to Voronoi include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Voronoi? | Voronoi's current market cap is $1.4B |
| What is the current revenue of Voronoi? | Voronoi's last 12-month revenue is $6.7M. |
| What is the current EBITDA of Voronoi? | Voronoi's last 12-month EBITDA is -$17.7M. |
| What is the current EV/Revenue multiple of Voronoi? | Current revenue multiple of Voronoi is 206.7x. |
| What is the current EV/EBITDA multiple of Voronoi? | Current EBITDA multiple of Voronoi is -77.9x. |
| Is Voronoi profitable? | Yes, Voronoi is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
